| Literature DB >> 25069764 |
Tao Yang1, Jianwen Gu1, Bin Kong1, Yongqin Kuang1, Lin Cheng1, Jingmin Cheng1, Xun Xia1, Yuan Ma1, Junhai Zhang1.
Abstract
The present study aimed to investigate the gene functions and expression profiles in perihematomal (PH) brain regions following spontaneous intracerebral hemorrhage. The gene expression profiles were downloaded from the Gene Expression Omnibus database under accession number GSE24265, which includes 11 brain samples from different regions, including four samples from PH areas, four from contralateral grey matter (CG) and three from contralateral white matter (CW). The gene expression profiles were pre-processed and the differentially expressed genes (DEGs) between PH and CG tissue, and PH and CW tissue were identified using R packages. The expression of genes in different tissues was analyzed by hierarchical clustering. Then, the interaction network between the DEGs was constructed using String software. Finally, Gene Ontology was performed and pathway analysis was conducted using FuncAssociate and Expression Analysis Systematic Explorer to identify the gene function. As a result, 399 DEGs were obtained between PH and CG, and 756 DEGs were identified between PH and CW. There were 35 common DEGs between the two groups. These DEGs may be involved in PH edema by regulating the calcium signaling pathway [calcium channel, voltage‑dependent, T-type, α1I subunit, Ca2+/calmodulin‑dependent protein kinase II α (CAMK2A), ryanodine receptor 2 (RYR2) and inositol 1,4,5-trisphosphate receptor, type 1 (ITPR1)], cell proliferation (sphingosine kinase 1), neuron differentiation (Ephrin-A5) or extracellular matrix-receptor interaction [collagen, type I, α 2, laminin B1 (LAMB1), syndecan 2, fibronectin 1 and integrin α5 (ITGA5)]. A number of genes may cooperate to participate in the same pathway, such as ITPR1-RYR2, CAMK2A-RYR2 and ITGA5-LAMB1 interaction pairs. The present study provides several potential targets to decrease hematoma expansion and alleviate neuronal cell death following spontaneous intracerebral hemorrhage.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25069764 PMCID: PMC4148373 DOI: 10.3892/mmr.2014.2421
Source DB: PubMed Journal: Mol Med Rep ISSN: 1791-2997 Impact factor: 2.952
Demographic and tissue sampling data.
| Case | Sex | Age | Time S-E | Time E-T | PH | CG | CW |
|---|---|---|---|---|---|---|---|
| 27 | F | 72 | 12 h | 5 h | 1 | 1 | 1 |
| 28 | F | 95 | 39 h | 2.5 h | 1 | 1 | 1 |
| 30 | M | 67 | 17 h | 3 h | 1 | 1 | |
| 31 | M | 86 | 4 days | 4 h | 1 | 1 | 1 |
F, female; M, male; S-E, stroke to exitus; E-T, exitus to tissue samples; PH, perihematomal areas; CG, contralateral grey matter; CW, contralateral white matter.
Figure 1Box plots of normalized gene expression data. Blue, pink, orange, respectively represents brain PH, CG and CW. The median of normalized data are almost at the same level, indicating good standardization. PH, perihematomal tissue; CG, contralateral gray matter; CW, contralateral white matter.
Figure 2DEGs of the two groups. The two circles represent the DEG set of PH vs. CW and PH vs. CG. The red numbers indicate number of DEGs. PH, perihematomal tissue; CG, contralateral gray matter; CW, contralateral white matter; DEGs, differentially expressed genes.
Figure 3Hierarchical clustering of gene expression. Red represents over-expression and green represents low expression. The left shows PH vs. CW and the right PH vs. CG. PH, perihematomal tissue; CG, contralateral gray matter; CW, contralateral white matter.
Figure 4Interaction network of DEGs. (A) The network for PH vs. CG and (B) the network for PH vs. CW. PH, perihematomal tissue; CG, contralateral gray matter; CW, contralateral white matter; DEGs, differentially expressed genes.
Enriched Gene Ontology terms of differentially expressed genes in two interaction networks.
| A, PH vs. CG | |||
|---|---|---|---|
|
| |||
| Term | Function | FDR | Genes |
| GO:0006816 | Calcium ion transport | 2.48E-04 | SLC8A2, CACNA1I, CACNB2, CACNG3, CACNA2D3, ITPR1, PRKCB, TPT1, RYR2, CACNA1E, PPP3CA, TRPV6, CAMK2A, JPH1 |
| GO:0006811 | Ion transport | 3.60E-04 | ATP6V0E1, SCN3B, CACNB2, FXYD7, KCNMB2, KCNQ5, KCNS1, SLC1A6, ATP5S, TPT1, TRPV6, PPP3CA, SLC30A3, JPH1, CAMK2A, GABRA2, SLC8A2, KCNB1, CACNA1I, GRIA3, CACNG3, CACNA2D3, ANKH, KCNV1, ITPR1, PRKCB, SLC17A7, KCNJ4, GRIA2, GRIA1, RYR2, CACNA1E |
| GO:0007268 | Synaptic transmission | 5.94E-04 | DLGAP1, GABRA2, STX1A, DLGAP2, NRXN3, CACNB2, PAH, VIPR1, SLC17A7, MAPK1, KCNQ5, GRIA2, GRIA1, CHRM1, SLC1A6, CACNA1E, PPP3CA, UNC13C, HTR2A |
| GO:0007267 | Cell-cell signaling | 0.001017 | NRP1, TOLLIP, CACNB2, PAH, VIPR1, KCNQ5, CRB1, SLC1A6, PPP3CA, FGF1, GABRA2, DLGAP1, STX1A, EFNB3, NRXN3, DLGAP2, EFNB2, SLC17A7, MAPK1, GRIA2, ADM, GRIA1, CHRM1, EFNA5, CACNA1E, UNC13C, HTR2A |
| GO:0019226 | Transmission of nerve impulse | 0.001418 | DLGAP1, GABRA2, STX1A, DLGAP2, NRXN3, CACNB2, PAH, VIPR1, KCNMB2, SLC17A7, MAPK1, KCNQ5, GRIA2, GRIA1, CHRM1, SLC1A6, CACNA1E, PPP3CA, UNC13C, HTR2A |
| GO:0030001 | Metal ion transport | 0.001908 | SLC8A2, SCN3B, KCNB1, CACNA1I, CACNB2, CACNG3, CACNA2D3, ITPR1, KCNV1, KCNMB2, PRKCB, SLC17A7, KCNQ5, KCNJ4, KCNS1, TPT1, RYR2, CACNA1E, TRPV6, PPP3CA, SLC30A3, JPH1, CAMK2A |
| GO:0006812 | Cation transport | 0.002788 | ATP6V0E1, SCN3B, CACNB2, KCNMB2, KCNQ5, KCNS1, ATP5S, TPT1, SLC30A3, PPP3CA, TRPV6, JPH1, CAMK2A, SLC8A2, KCNB1, CACNA1I, CACNG3, CACNA2D3, KCNV1, ITPR1, PRKCB, SLC17A7, KCNJ4, RYR2, CACNA1E |
| GO:0015674 | Di-, tri-valent inorganic cation transport | 0.002936 | SLC8A2, CACNA1I, CACNB2, CACNG3, CACNA2D3, ITPR1, PRKCB, TPT1, RYR2, CACNA1E, PPP3CA, TRPV6, CAMK2A, JPH1 |
| GO:0030182 | Neuron differentiation | 0.036294 | DCC, NRP1, EFNB3, NRXN3, NTN4, DPYSL5, PTPRR, SLIT2, GPR98, ARX, NTRK3, FEZF2, DLX1, ADM, BAG1, CRB1, S100B, NEUROD2, EFNA5, OLFM3 |
| GO:0022836 | Gated channel activity | 0.003996 | GABRA2, SCN3B, KCNB1, CACNA1I, CACNB2, CACNG3, GRIA3, CACNA2D3, ITPR1, KCNV1, KCNMB2, KCNQ5, KCNJ4, KCNS1, GRIA2, GRIA1, RYR2, CACNA1E |
| GO:0005216 | Ion channel activity | 0.005017 | GABRA2, SCN3B, KCNB1, CACNA1I, CACNB2, CACNG3, GRIA3, CACNA2D3, ITPR1, KCNV1, FXYD7, KCNMB2, KCNQ5, KCNJ4, KCNS1, GRIA2, GRIA1, RYR2, CACNA1E, TRPV6 |
| GO:0022838 | Substrate specific channel activity | 0.007815 | GABRA2, SCN3B, KCNB1, CACNA1I, CACNB2, CACNG3, GRIA3, CACNA2D3, ITPR1, KCNV1, FXYD7, KCNMB2, KCNQ5, KCNJ4, KCNS1, GRIA2, GRIA1, RYR2, CACNA1E, TRPV6 |
| GO:0015267 | Channel activity | 0.01281 | GABRA2, SCN3B, KCNB1, CACNA1I, CACNB2, CACNG3, GRIA3, CACNA2D3, ITPR1, KCNV1, FXYD7, KCNMB2, KCNQ5, KCNJ4, KCNS1, GRIA2, GRIA1, RYR2, CACNA1E, TRPV6 |
| GO:0022803 | Passive transmembrane transporter activity | 0.013258 | GABRA2, SCN3B, KCNB1, CACNA1I, CACNB2, CACNG3, GRIA3, CACNA2D3, ITPR1, KCNV1, FXYD7, KCNMB2, KCNQ5, KCNJ4, KCNS1, GRIA2, GRIA1, RYR2, CACNA1E, TRPV6 |
|
| |||
| B, PH vs. CW | |||
|
| |||
| Term | Function | FDR | Genes |
|
| |||
| GO:0001568 | Blood vessel development | 5.290E-04 | EDNRA, GPX1, EMCN, CTGF, HMOX1, DHCR7, COL1A2, QKI, ELK3, CDH5, SCG2, ANXA2 |
| GO:0001944 | Vasculature development | 6.480E-04 | EDNRA, GPX1, EMCN, CTGF, HMOX1, DHCR7, COL1A2, QKI, ELK3, CDH5, SCG2, ANXA2 |
| GO:0042127 | Regulation of cell proliferation | 0.001 | FGFR2, DLC1, TESC, KAT2B, HCLS1, PTGS1, SPHK1, CDH5, ARNT, TRIB1, MYCN, EDNRA, AZGP1, GPX1, VDR, PTGES, HMOX1, DHCR7, FABP3, GPNMB, LAMB1, KLF4, SCG2 |
| GO:0006952 | Defense response | 0.002 | TF, A2M, YWHAZ, IL1R1, LYZ, HLA-C, HLA-B, PXK, STAT3, GCH1, VDAC1, CD163, CD83, INHBA, HMOX1, IL1RAPL1, RAB27A, FN1, HLA-DRA, SCG2 |
| GO:0008283 | Cell proliferation | 0.003 | BCAT1, NANOG, MAP2K1, NASP, ZEB2, FKBP1A, HPRT1, EDNRA, GPX1, UHRF1, DAB2, NDE1, HMOX1, GAB1, CKS2 |
| GO:0016310 | Phosphorylation | 0.003 | FGFR2, IRAK1, TRPM6, MAP2K1, STK24, NEK1, PIK3C2B, PRKCH, STK17A, PXK, PRKX, TRIB1, RPS6KA3, MAP4K5, PLK2, SCYL2, GAB1, RELN, MERTK, PGK1, LIPE, UGP2 |
| GO:0006793 | Phosphorus metabolic process | 0.003 | FGFR2, NEK1, STK17A, PXK, PRKX, TRIB1, DUSP14, GAB1, IRAK1, TRPM6, MAP2K1, STK24, PIK3C2B, PRKCH, DUSP5, RPS6KA3, MAP4K5, PLK2, SCYL2, RELN, PGK1, MERTK, LIPE, UGP2, DUSP7 |
| GO:0006796 | Phosphate metabolic process | 0.003 | FGFR2, NEK1, STK17A, PXK, PRKX, TRIB1, DUSP14, GAB1, IRAK1, TRPM6, MAP2K1, STK24, PIK3C2B, PRKCH, DUSP5, RPS6KA3, MAP4K5, PLK2, SCYL2, RELN, PGK1, MERTK, LIPE, UGP2, DUSP7 |
| GO:0008285 | Negative regulation of cell proliferation | 0.004 | DLC1, TESC, KAT2B, CDH5, TRIB1, VDR, AZGP1, PTGES, HMOX1, FABP3, GPNMB, KLF4, SCG2 |
| GO:0006468 | Protein amino acid phosphorylation | 0.004 | FGFR2, IRAK1, TRPM6, MAP2K1, STK24, NEK1, PRKCH, STK17A, PXK, PRKX, TRIB1, RPS6KA3, MAP4K5, PLK2, SCYL2, GAB1, RELN, MERTK, LIPE |
| GO:0043085 | Positive regulation of catalytic activity | 0.005 | DLC1, IRAK1, MAP2K1, SPHK1, ZEB2, PMAIP1, TPM1, EDNRA, VDR, MAP4K5, PSMD12, GSPT1, IFT57, GAB1, GCH1, RELN |
| GO:0032268 | Regulation of cellular protein metabolic process | 0.005 | HSP90AB1, DLC1, A2M, HCLS1, EIF5, ZEB2, FKBP1A, EDNRA, MAP4K5, PSMD12, TIA1, GAB1, QKI, HSPB1, PPP1R15A |
| GO:0044093 | Positive regulation of molecular function | 0.006 | DLC1, IRAK1, MAP2K1, SPHK1, FKBP1A, ZEB2, PMAIP1, TPM1, GCH1, EDNRA, VDR, MAP4K5, PSMD12, GSPT1, IFT57, GAB1, RELN |
| GO:0051174 | Regulation of phosphorus metabolic process | 0.007 | DLC1, IRAK1, MAP2K1, HCLS1, SPHK1, ZEB2, FKBP1A, APLP2, TRIB1, EDNRA, INHBA, MAP4K5, GAB1, CKS2, RELN |
| GO:0019220 | Regulation of phosphate metabolic process | 0.007 | DLC1, IRAK1, MAP2K1, HCLS1, SPHK1, ZEB2, FKBP1A, APLP2, TRIB1, EDNRA, INHBA, MAP4K5, GAB1, CKS2, RELN |
| GO:0042981 | Regulation of apoptosis | 0.007 | DLC1, IRAK1, YWHAZ, PREX1, SPHK1, ACTN1, STK17A, PMAIP1, GCH1, INHBA, GPX1, VDR, GSPT1, HMOX1, TIA1, IFT57, HSPB1, CTSB, API5, RAB27A, SCG2 |
| GO:0043067 | Regulation of programmed cell death | 0.007 | DLC1, IRAK1, YWHAZ, PREX1, SPHK1, ACTN1, STK17A, PMAIP1, GCH1, INHBA, GPX1, VDR, GSPT1, HMOX1, TIA1, IFT57, HSPB1, CTSB, API5, RAB27A, SCG2, DLC1 |
| GO:0010941 | Regulation of cell death | 0.008 | IRAK1, YWHAZ, PREX1, SPHK1, ACTN1, STK17A, PMAIP1, GCH1, INHBA, GPX1, VDR, GSPT1, HMOX1, TIA1, IFT57, HSPB1, CTSB, API5, RAB27A, SCG2 |
FDR, false discovery rate adjusted by BH multiple test correction method; PH, perihematomal areas; CG, contralateral grey matter; CW, contralateral white matter; BH, Benjamini Hochberg; GO, Gene Ontology; DEGs, differentially expressed genes; CAMK2A; Ca2+/calmodulin-dependent protein kinase II α; RYR2, ryanodine receptor 2; ITPR1, inositol 1,4,5-trisphosphate receptor, type 1; LAMB1, laminin B1; CACNA1 calcium channel, voltage-dependent, T-type, α1I subunit; COL1A, collagen type 1, α2; FN1, fibronectin 1; SPHK1, sphingosine kinase-1; EFNA5, ephrin-A5.
Enriched pathways of differentially expressed genes in two interaction networks.
| A, PH vs. CG | ||
|---|---|---|
|
| ||
| Pathway | FDR | Genes |
| hsa04020: Calcium signaling pathway | 7.320E-05 | SLC8A2, ADORA2B, CACNA1I, SPHK1, HTR4, ITPR1, PRKCB, CHRM1, RYR2, CACNA1E, PPP3CA, CAMK2A, HTR2A |
| hsa04010: MAPK signaling pathway | 3.020E-04 | MEF2C, NLK, CACNA1I, PTPRR, CACNB2, CACNG3, CACNA2D3, DDIT3, PRKCB, MAPK1, DUSP16, CACNA1E, PPP3CA, FGF1, RAPGEF2 |
| hsa04720: Long-term potentiation | 0.001 | MAPK1, GRIA2, GRIA1, PPP3CA, CAMK2A, ITPR1, PRKCB |
| hsa04080: Neuroactive ligand-receptor interaction | 0.007 | GABRA2, ADORA2B, GRIA2, PTH2R, THRB, GRIA1, CNR1, CHRM1, HTR4, GRIA3, VIPR1, HTR2A, SLC8A2, CACNA1I, CACNB2, CACNG3, CACNA2D3, ITPR1, PRKCB, TPT1, RYR2, CACNA1E, PPP3CA, TRPV6, CAMK2A, JPH1 |
|
| ||
| B, PH vs. CW | ||
|
| ||
| Pathway | FDR | Genes |
|
| ||
| hsa04512: ECM-receptor interaction | 0.019 | ITGA5, COL1A2, RELN, LAMB1, SDC2, FN1 |
| hsa05330: Allograft rejection | 0.028 | HLA-DRB1, HLA-A, HLA-C, HLA-B, HLA-DRA |
| hsa04510: Focal adhesion | 0.031516 | MAP2K1, ITGA5, COL1A2, ACTN1, RELN, LAMB1, VASP, VCL, FN1 |
| hsa04514: Cell adhesion molecules | 0.032 | HLA-DRB1, HLA-A, CNTN2, HLA-C, HLA-B, CDH5, SDC2, HLA-DRA |
| hsa05332: Graft-versus-host disease | 0.05 | HLA-DRB1, HLA-A, HLA-C, HLA-B, HLA-DRA |
| hsa04940: Type I diabetes mellitus | 0.042 | HLA-DRB1, HLA-A, HLA-C, HLA-B, HLA-DRA |
FDR, false discovery rate adjusted by Benjamini-Hochberg multiple test correction method; PH, perihematomal areas; CG, contralateral grey matter; CW, contralateral white matter; CAMK2A; Ca2+/calmodulin-dependent protein kinase II α; RYR2, ryanodine receptor 2; ITPR1, inositol 1,4,5-trisphosphate receptor, type 1; LAMB1, laminin B1; CACNA1 calcium channel, voltage-dependent, T-type, α1I subunit; COL1A, collagen type 1, α2; FN1, fibronectin 1; SPHK1, sphingosine kinase-1.